Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Randomized Phase II of Lomustine Versus Lomustine-Dasatinib in Patients With Recurrent Glioblastoma

To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma

Inclusion Criteria:

• Patients with histological or cytological proven glioblastoma multiforme
• Recurrent or progressive disease documented by magnetic resonance imaging (MRI)
• World Health Organization (WHO) Performance status 0 - 2
• Patient may have been operated for recurrence
• For non operated patients, recurrent disease must be at least one bidimensionally measurable target lesion with one diameter of at least 2cm
• Patients must be on a stable or decreasing dose of corticosteroids for at least 1 week prior to baseline MRI

Exclusion Criteria:

• Patients with histological or cytological proven glioblastoma multiforme
• Completion of radiotherapy to the brain less than 3 months prior to registration/randomization
• Prior treatment with high dose radiotherapy, stereotactic radiosurgery or internal radiation therapy
• Previous or current malignancy at other sites within prior 3 years